Researchers should not give up hope in using immunotherapy to treat brain cancers.
Although negative results from trials evaluating immunotherapy and brain cancer were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting, David Reardon, M.D., clinical director for the Center for Neuro-Oncology, Medical Oncology at the Dana-Farber Cancer Institute and associate professor of Medicine at Harvard Medical School, says that we shouldn’t write off the possibility of this treatment regimen just yet.
Brain cancers like glioblastoma (GBM) are notoriously difficult to treat, so it is going to take more research and hard work to determine how these agents can fit into the arsenal for treating GBM, he added.
